I'm LongbridgeAI, I can summarize articles.Alnylam Pharma (ALNY) fell 14.16% this week to close at $219.72, underperforming the S&P 500’s -0.27% move by roughly 13.89 percentage points. The week was one-way selling: shares opened Monday at $256.28 and drifted lower into Friday’s close, hitting an intraday low of $219.40. The weekly range ran from $257.27 to $219.40, a 14.78% swing. Average daily volume came in around 1.33m shares, about 9.
The Week
Alnylam Pharma (ALNY) fell 14.16% this week to close at $219.72, underperforming the S&P 500’s -0.27% move by roughly 13.89 percentage points. The week was one-way selling: shares opened Monday at $256.28 and drifted lower into Friday’s close, hitting an intraday low of $219.40. The weekly range ran from $257.27 to $219.40, a 14.78% swing. Average daily volume came in around 1.33m shares, about 9.1% below the prior 60-day median, suggesting the pullback wasn’t driven by heavy distribution.
Key Events
Company-specific news was thin this week. Early in the week, Alnylam was flagged alongside other biotech names for its valuation logic tied to clinical milestones. On Wednesday, the company said it had brought in a former football player to support its heart-disease education push, extending its effort to reach patients with inherited conditions. A retrospective piece on Friday noted that $100 invested in Alnylam 20 years ago would now be worth a meaningful sum, highlighting the company’s long-term compounding story.
Analyst Ratings
Across 29 covering institutions, 16 rate the stock buy, 6 overweight and 7 hold; there are no underweight or sell ratings. The consensus rating is buy, with a consensus target of $371.12, about 68.9% above the latest close. The target range is wide, from $256 to $536, pointing to a real dispersion in longer-term views. Alnylam ranks 6th within a 507-name biotech sector, near the higher end of the group.
The Week Ahead
The US macro calendar picks up next week. Monday brings final S&P Global services PMI and ISM non-manufacturing PMI, with services sentiment potentially shaping appetite for long-duration biotech assets. Tuesday has international trade data, and Wednesday includes EIA crude inventory figures. Alnylam itself has no scheduled earnings or regulatory catalyst in the coming days.
In Short
The week’s price weakness contrasted with a quiet news flow. Brokers maintain a buy consensus and a target well above spot, yet the market remains cautious on a high-multiple biotech name. The stock trades at roughly 37.95x earnings, and the latest session showed net selling by large-lot money. The question ahead is whether macro data eases risk-off pressure and whether fresh clinical or commercial updates emerge from the company.
This article is generated by LongbridgeAI from market data, for information only and not investment advice.